You just read:

Transition Therapeutics Announces Results of Data Analysis from ELND005 Phase 2/3 Clinical Study in Agitation and Aggression in Alzheimer's Disease Patients

News provided by

Transition Therapeutics Inc.

Oct 15, 2015, 06:01 ET